Login to Your Account



Prochymal's Canadian Nod Marks Stem Cell Milestone

By Nuala Moran
Staff Writer

Wednesday, May 23, 2012
LONDON – The timing could not have been better. The international stem cell community getting together in London was able to applaud the breakthrough signified by Health Canada's approval of Prochymal, Osiris Therapeutics Inc.'s allogeneic stem cell treatment for graft-vs.-host disease, and rejoice in the knowledge that there is light at the end of the regulatory tunnel.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription